How much revenue does Nabriva Therapeutics make?

Nabriva Therapeutics reported $35.67 million in revenue for fiscal year 2022, up 31.1% from $27.22 million in fiscal year 2021. In Q2 2023 revenue was $2.57 million.

What companies are similar to Nabriva Therapeutics?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Core One Labs Inc. (CLABF), Neptune Wellness Solutions Inc. (NEPTF), Tengion, Inc. (TNGNQ), Plant-Based Investment Corp. (CWWBF).

Nabriva Therapeutics plc (NBRVF) Stock

About Nabriva Therapeutics plc

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONT...

At a glance

Nabriva Therapeutics reported revenue of $35.67 million for fiscal year 2022, up 31.1% from fiscal year 2021, and net income of -$57.19 million. In Q2 2023 (the quarter ended June 30, 2023) revenue was $2.57 million, down 70.7% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.